Kornimate/medical-research-clean huggingface dataset:
preventive application of single-use negative pressure wound therapy (snpwt) in the postoperative course of radiotreatated limb sarcoma surgery

Conditions: Sarcoma; Sarcoma,Soft Tissue

Summary: patients will be recruited at the time of the pre-admission visit. during the screening visit the patient will undergo a physical examination and his medical history will be collected. oncological history and tumor characteristics will be considered and ct-scan imaging will be analysed. ecog performance status will be reported. if inclusion criteria are respected, the patient will be randomized. the application of the pico14 study device or standard dressing (dry gauze and plaster) will then be carried out on the day of surgery. for subjects randomized to the treatment arm (arm a), dressing change with the application of the new pico14 will occur at day 4+1, day 8±1, and day 14±2. for subjects randomized to the control arm (arm b), the standard dressing with gauze and plaster is applied. regardless of the randomization arm the wound assessment via asepsis score will occur at day 4+1, 8±1 and 14±2. during fup, the dressing can be changed autonomously by the patient if necessary. the information will be recorded on the occasion of the next visit or an extraordinary visit. on day 21, sutures will be removed. on day 30±2, the total asepsis score will be calculated, in order to evaluate the wound healing. from day 14±2, regardless of the randomization arm all patients will be treated with standard dressing. follow-up visits can be scheduled up to 90 days after surgery.


Eligibility criteria:
inclusion criteria: * male or female ≥ 18 years of age * diagnosis of primary high-grade (grade iii) soft tissue sarcoma of the limbs (confirmed histopathologically) * performed neoadjuvant radiotherapy (short or long-term) * candidates for wide radical excision surgery * negative ct scan staging for distant metastasis * signing of informed consent exclusion criteria: * diagnosis of benign neoplasm * diagnosis of retroperitoneal or trunk sarcomas; * candidates to hindquarter or forequarter amputation surgery; * incomplete wide excision; * vascular resection; * other loco-regional treatments (e.g. isolated limb perfusion or electrochemotherapy).

Keywords: sarcoma limbs high-grade (grade iii) soft tissue sarcoma pico14
thrombus aspiration in stemi patients with high thrombus burden

Conditions: ST-segment Elevation Myocardial Infarction (STEMI)

Summary: this is a prospective, multicenter, open-label, randomized, controlled, parallel group study, in which st-segment elevation myocardial infarction (stemi) patients with high thrombus burden(timi thrombus grade ≥3) are included. patients are randomized to be treated with or without manual thrombus aspiration(ta) during primary percutaneous coronary intervention(ppci) by a ratio of 1:1.

this study is intended to explore the efficacy of thrombus aspiration (ta) in st-segment elevation myocardial infarction (stemi) patients with high thrombus burden who received primary pci within 12 hours after the onset of symptoms, reducing the incidence of cardiovascular death, recurrent myocardial infarction, stent thrombosis, target vessel revascularization within 180 days or stroke in 30 days.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years; 2. stemi patients undergoing primary pci within 12 hours after the onset of symptoms; 3. high thrombus burden after guidewire passes the lesion (timi thrombus grade ≥3); 4. informed consent must be voluntary; exclusion criteria: 1. haemodynamic instability or cardiogenic shock; 2. after thrombolytic therapy; 3. the predicted survival time is less than 6 months due to non-cardiac disease; 4. history of coronary artery bypass grafting; 5. participate in other researches within 30 days; 6. preoperative gastrointestinal bleeding or contraindications to dual antiplatelet therapy; 7. patients were considered unsuitable by other researchers.

Keywords: thrombus aspiration coronary intervention thrombus burden st-segment elevation myocardial infarction
translation and validation of the upper and lower limbs, pain, autonomy and quality of life scales in albanian

Conditions: Musculoskeletal Pain; Autonomy; Healthy; Upper Limb Injury; Lower Limb Injury

Summary: the cross-cultural adaptation will be performed according to the internationally recommended methodology, using the following guidelines: translation, back-translation; revision by a committee, questionnaire diffusion and data collection and analyzing. the psychometric properties will be evaluated by administering the questionnaire to approximately 300 participants. reliability will be estimated through stability and homogeneity assessment

the assessment scales of the upper and lower limbs, pain, autonomy and quality of life for use in the albanian-speaking population are as follow: 1. adaptation, validation and test-retest reliability of upper limbs scales as: disabilities of the arm, shoulder and hand questionnaire (dash), mayo elbow score, oxford elbow score, patent-rated tennis elbow evaluation, shoulder pain and disability index (spadi), simple shoulder test (sst) and upper limp functional index (ulfi). 2. adaptation, validation and test-retest reliability of lower limb scales as: oxford hip score, motricity index and trunk control test in albanian language. 3. adaptation, validation and test-retest reliability of health scales and autonomy: berg balance scale, functional ambulation category (fac), fear-avoidance beliefs questionnaire (fabq), graded chronic pain scale (gcps),motor assessment scale (mas), stroke rehabilitation assessment of movement (stream), hospital anxiety and depression scale (hads), headache impact test (hit6), leeds assessment of neuropathic symptoms and signs pain scale (lanss), instrumental activities of daily living scale (iadl), neck disability index (ndi), health status questionnaire (eq-5d-5l), social responsiveness scale (srs), short portable mental status questionnaire (spmsq), tampa skale kinesiophobia, ankle--hindfoot scale (aofas) and the western ontario and mcmaster universities osteoarthritis index (womac).

Eligibility criteria:
inclusion criteria: * articular and muscular pain * back pain * presence of rheumatologic symptoms * functional misbalance * scoliosis * musculoskeletal disorders exclusion criteria: * no native albanian language * severe trauma to the lumbar spine or hip(s) * tumor * metabolic disease
the influence of leg length discrepancy after total hip arthroplasty on function and quality of life

Conditions: Osteoarthritis; Leg Length Difference; Hip Arthroplasty

Summary: leg length discrepancy (lld) is a complication of tha and may result in patient dissatisfaction, gait disorder, greater trochanter pain, low back pain. in the literature, lld is reported to vary widely among studies e.g. 6 to 35 mm. however, the threshold at which a lld is clinically important is still a matter of debate. the aim of this study was to determine the influence of non-corrected lld after tha on patients' reported hip function and quality of life. this prospective cohort study was conducted at sundsvall teaching hospital in sweden after it was approved by the regional ethics committee at umeå university (no. 07-052m and no. 12-287-32m). between september 2010 and april 2013, all patients with unilateral primary osteoarthritis (oa) treated with tha were considered for inclusion. informed consent was obtained from all patients. patients with secondary oa, previous spinal, pelvic, or lower limb injuries or fractures were excluded. the primary outcome measure was the western ontario and mcmaster universities osteoarthritis (womac) index that measures functional outcome (ref). the secondary outcome measure was the eq-5d and visual analogue scale (vas) scale. patients were assessed preoperatively and at follow-up at 1 year postoperatively. the posterolateral approach was used in all operations. lld was measured on the postoperative x-rays. patients were divided into three groups: shortening group where the operated leg was more than 5mm shorter compared with the contralateral side, the restoration control group where the operated leg was within 5mm shortening and 9mm lengthening compared with the contralateral side, and the lengthening group where the operated leg became more than 9mm longer compared with the contralateral side.


Eligibility criteria:
inclusion criteria: * unilateral primary osteoarthritis (oa) treated with tha were considered for inclusion. exclusion criteria: * secondary oa. * previous spinal, pelvic, or lower limb injuries or fractures. * bilateral coxarthrosis.
laparoscopic colectomies in management of colonic cancers

Conditions: Laparoscopic Colectomy; Cancer Colon; Intracorporeal Anastomosis

Summary: the aim of this study is to compare the surgical outcomes after laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers .

this is clinical trial ,interventional quasi experiment study to evaluate the surgical outcomes between intracorporeal versus extracorporeal anastomosis in laparoscopic right and left hemicolectomies including post operative pain, hospital stay, leakage from anastomosis, early recurrence, hernias patient satisfaction operative time and more surgical outcomes. in egyptian hospitals. source of data the investigators follow up and medical reports and more . surgical procedures this trial including two groups of patients with right and left cancer colon undergoing laparoscopic colectomy. first group (a) will be operated as intracorporeal anastomosis while the second group (b) will be operated as extracorporeal anastomosis. sample size more than 50 person statistical analysis plan statistical package for the social sciences (spss) program

Eligibility criteria:
inclusion criteria: * patients had to present histologically confirmed cancer( right and left) colon. * all grades of cancer will be included. * cancer at cecum ,appendix, ascending colon, hepatic flexure or at splenic flexure , descending colon and sigmoid colon. exclusion criteria: * locally advanced disease with invasion of adjacent important organs. * acute bowel obstruction or perforation from cancer. * pregnant ladies. * rectal cancer and transverse colon cancer.

Keywords: laparoscopic intracorporeal extracorporeal anastomosis hemicolectomies , colonic cance
obstetric anesthesia and analgesia and multiple sclerosis

Conditions: Multiple Sclerosis

Summary: aim of the retrospective study was to evaluate the influence of the labour on the clinical course of the parturients with ms in selected 6 month follow-up interval and to evaluate to possible influence of the different anesthesia/analgesia types on the course of ms.

the role of anesthesia in multiple sclerosis (ms) progression remains unclear in spite of few foreign studies. the most frequently afflicted patients by ms are women of childbearing age and influence of anesthesia or obstetric epidural analgesia has only not been investigated in czech republic. the study aims to retrospectively compare the further course of the disease of ms in patients who labor between 2004 and 2013 in university hospital brno either by caesarean section or vaginally with epidural analgesia , with patients who gave birth spontaneously without anesthesia.the aim of the study was to evaluate the influence of the labour on the clinical course of ms and further evaluate the possible influence of the type of anesthesia/analgesia in the peripartal period on the ms progression.

Eligibility criteria:
inclusion criteria: * parturients with multiple sclerosis * possible follow up - neurologic examination available after 10 month from delivery exclusion criteria: * probable or no multiple sclerosis at time of labor * unknown neurology history * unknown data on neurology outcome 6 months after labour * incomplete data * follow-up not possible

Keywords: multiple sclerosis, anesthesia
clinical benefit of topoisomerase downregulation

Conditions: Ovarian Cancer

Summary: 1.1 to determine the regulation of topoisomerase i and ii following alternating prolonged exposure to topotecan and etoposide (vp-16) 1.2 to determine the time to progression and the objective response rate of this treatment in patients with incurable ovarian cancer.

the rationale to study the downregulation of topoisomerase enzyme in ovarian cancer in relationship to the cell cycle distribution of the cancer cells after a prolonged continuous exposure to topo i and ii poisons is to better understand the relationship between cell cycle and topo poisoning, which may lead to better clinical trial designs.

Eligibility criteria:
inclusion criteria: * all patients, 18 years of age or older, with incurable ovarian advanced cancer are eligible provided that they have measurable disease by ct-scan imaging, or evaluable disease by tumor markers, following the criteria described by rustin et al. (14). (response to a specific treatment has occurred if after two ca-125 samples there has been a 50% decrease, confirmed by a fourth sample (50% response), or a serial decrease over three samples of greater than 75% (75% response). the final sample has to be at least 28 days after the previous sample.) * patients must have a life expectancy of at least 12 weeks. * patients must have a zubrod performance status of 0-2. * patients must sign an informed consent. * patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of \> 1,500 or cells/mm3 and platelet count \>100,000/mm3 and absence of a regular red blood cell transfusion requirement. * patients should have adequate hepatic function with a total bilirubin \< 2 mg/dl and sgot or sgpt \< two times the upper limit of normal, and adequate renal function as defined by a serum creatinine \< 1.5 x upper limit of normal. exclusion criteria: * patients with symptomatic brain metastases are excluded from this study. * pregnant women or nursing mothers are not eligible for this trial. patients of child bearing potential must use adequate contraception. * patients may receive no other concurrent chemotherapy or radiation therapy during this trial. * patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections are not eligible for this trial.

Keywords: phase i ovarian cancer ovary cancer
neoadjuvant metformin in association to chemoradiotherapy for locally advanced rectal cancer

Conditions: Rectal Neoplasms; Adenocarcinoma; Carcinoma

Summary: a phase ii, randomized study of placebo versus metformin in association to chemotherapy with capecitabine and radiation in the neoadjuvant treatment of locally advanced (t3-4n0m0 or txn1-2m0) rectal carcinomas.

neometre is a randomized, double blind trial aiming to evaluate the efficacy and tolerability of metformin in association to chemoradiotherapy for the preoperative treatment of locally advanced (t3-4n0m0 or txn1-2m0) rectal carcinomas. patients eligible for this study will be submitted to neoadjuvant 3d radiotherapy with 50,4 gray (gy) divided in 25 applications, in association to capecitabine, 825mg/m2 bid for five days every week. the participants will be randomized to daily metformin or placebo during the chemoradiotherapy period. the primary end-point is pathological complete response. the secondary end-points are recurrence-free survival (rfs), disease-free survival (dfs), overall survival (os), local recurrence rate, overall response rate, sphincter preservation rate, quality of life (qol) and toxicity.

Eligibility criteria:
inclusion criteria: * 18 years or older; * biopsy proven poorly differentiated carcinoma or adenocarcinoma of the rectum; * lesions located within 12 cm of the anal verge (from colonoscopy assessment); * ability to tolerate oral treatment; * locally advanced tumor, classified by the presence of positive regional lymph nodes or primary tumor invasion beyond the serosa (t3 or t4), assessed by mri; * eligibility for curative surgery (no distant metastasis or invasion of bony structures of the pelvis); * performance status (ps) eastern cooperative oncology group (ecog) 0-2; * adequate hematologic functions (hemoglobin ≥ 10 g / dl \[5.6 mmol / l\]; neutrophil count ≥ 1,500 / mm3 and platelet count ≥ 100,000 / mm3), adequate renal function (serum creatinine less than 1.5 times the unl) and adequate hepatic function (bilirubin less than 1.5 times the unl; aspartate aminotransferase and alanine aminotransferase less than 2.5 times the unl); exclusion criteria: * known hypersensitivity to metformin or its excipients; * squamous carcinomas of the rectum or anal canal; * chronic treatment with corticosteroids or other immunosuppressive agents; * treatment with oral antidiabetic products; * distant metastasis at diagnosis or tumor invasion of pelvic bone structures that may proscribe curative intent surgery; * chronic or acute infections; * use of drugs under study up to four weeks prior to randomization; * pregnant or nursing patients; * prior radiotherapy to the pelvic region; * myocardial infarction up to six months prior to randomization, or uncontrolled ischemic heart disease; * congestive heart insufficiency new york heart association (nyha) iii-iv.

Keywords: metformin rectal cancer rectum radiotherapy capecitabine neoadjuvant adenocarcinoma carcinoma
relevance of gastric aspirate in hcmv detection

Conditions: Cytomegalovirus Infections; Hypotrophic Newborns

Summary: human cytomegalovirus (cmv) is the leading cause of neonatal viral infection and can have a significant impact on the neurosensory development of newborns and especially premature infants. cmv infection can result from materno-fetal transmission during pregnancy (congenital infection) or postnatal transmission. the prevalence of congenital cmv infection in the newborn is estimated to be between 0.1 and 0.5%. among the newborns in utero infected by cmv, it is estimated that 10-15% will present symptoms at birth (hypoacousia / unilateral or bilateral deafness, microcephaly, chorioretinitis, psychomotor retardation, etc.) and 0.5% of them will die. 20% of infected infants, mainly symptomatic newborns, suffer permanent sequelae, mainly loss of hearing. many asymptomatic children at birth will present hearing loss and other delayed neurological complications. a progressive neurosensory hearing loss may develop for 13-15% of asymptomatic newborns at birth. deafness is bilateral in 50% of cases, severe in more than 50% of cases, and its occurrence is often delayed. the hearing loss has a significant impact on the future life of the child, mainly on language acquisition and school performance. a systematic cmv screening is not currently recommended at birth due to the frequency of asymptomatic forms, difficulty in fetal diagnosis and prognosis, lack of consensus for preventive and curative treatment of the infection. new treatments are being evaluated and encouraging results could revive the debate. pcr from urine is the gold standard for the diagnosis of cmv infection. urine collection is not systematic in newborns and its realization can sometimes be difficult. on the other hand, in children at risk (hypotrophy, prematurity, infectious risks, fetal distress or respiratory distress at birth), gastric aspiration is systematically performed at birth to overcome obstruction of the upper aero-digestive tract, to prevent oesophageal atresia, to avoid inhalation by reflux and sometimes to make a bacteriological diagnosis. our hypothesis is that this liquid could be used for the detection of cmv infection without adding any invasive action in newborns. ultimately, gastric aspirate could allow for routine cmv screening in children at risk and thus allow for appropriate care by nursing staff.the occurrence of immediate or delayed sensory sequelae in these children would be then limited.


Eligibility criteria:
inclusion criteria of the newborn: - child born in maternity and / or child hospitalized in the neonatal médicine department of the university hospital of besançon for which a urine sample (minimum volume = 0.5 ml) and a gastric aspiration fluid sample (minimum volume = 0.7ml) were collected (regardless of gender, birth weight or pathology presented at admission). exclusion criteria of the newborn: * child died before the sampling * a volume of gastric aspiration fluid dedicated to the study less than 0.7 ml. * an impossible collection of urine (malformation, skin irritation of the perineum, contamination with meconium).
osteopathy of post cesarean section adhesions

Conditions: Low Back Pain; Cesarean Section Complications

Summary: chronic low back pain post cesarean section adhesions represents a restricting dysfunction, mainly influences abdominal fascia that leads to major welfare and economic restrictions. osteopathic manipulation is a drug-free non-invasive is the therapeutic application of manually guided forces to improve physiologic function and support homeostasis. the purpose of the current study is to determine the effect of osteopathic manipulations of post cesarean section adhesions on low back pain

chronic low back pain is a common musculoskeletal disorder affects adults with 84% prevalence. it influences lower back, and lasts at least 12 weeks. where increased annual cesarean section rates up to 19.1% associated with scar, pelvic, abdominal and low back pain disorders (chia et al., 2016). from the fascial point of view, abdominal muscles are in continuity with the thoracolumbar fascia and the pelvic floor. it has been demonstrated that they work with great synergy and guaranteed by fascial continuity (fan et al., 2018). osteopathic manipulative technique consists of a range of direct, indirect, combined, fluid and reflex-based manual techniques that are applied specifically to a joint or non-specifically to a body area. direct techniques apply thrust, impulse, muscle contraction, fascial loading or passive range of motion (fan et al., 2018).the purpose of the current study is to determine the effect of osteopathic manipulations of post cesarean section adhesions on low back pain. up on that 30 post cesarean women suffering from low back pain at least for 6 months from the outpatient clinic of mitghamer hospital, el-daqahlia. their age range 20-35 years old, bmi range≤ 25 kg /m2. they will be allocated into control group will receive analgesics. study group will receive four weeks of analgesics, plus osteopathic manipulations once per week.

Eligibility criteria:
inclusion criteria: * they suffered from low back pain and undergoes cesarean section at least 6 months before entry into study. * their body mass index (bmi) will be ≤ 25 kg /m2. * their age will range from 20 to 35 years. * they would not use any other analgesic drugs during the study period. exclusion criteria: * pregnancy or suspected pregnancy. * recent abdominal surgery * patients with severe spinal pathology (cauda equine syndrome, spinal canal stenosis, fracture of spine, discitis, infectious disease of spine). * cancer. * abdominal and pelvic infection, open wound, burn and skin irritation.

Keywords: osteopathic manipulation low back pain post cesarean section adhesions visual analogue scale oswestry low back disability questionnaire modified schober test